Valuation Trading Multiples & Precedent Transactions: Biologic Drug Discovery Tools Companies
Valuation benchmarks for Biologic Drug Discovery Tools Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Biologic Drug Discovery Tools Companies Market Context & Valuation Drivers
Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Typical capabilities span recombinant protein and cytokine manufacturing, catalog antibodies and assay reagents for molecular biology workflows, PCR/qPCR/NGS kits, oligonucleotide synthesis, and turnkey protein expression systems. Many offer custom protein and antibody production, antibody discovery and optimization services, and AI-driven biologics design including codon optimization. Integrated bioinformatics, QC, and scale-up services support research and preclinical development, creating diversified revenue across product sales, project-based services, and platform licensing.
Primary customers include biopharmaceutical R&D groups, diagnostics developers and laboratories, and academic research institutions and CROs. Buyers seek faster discovery cycles, higher assay reliability, and access to specialized biologics at scale. Key valuation drivers include revenue growth from catalog and custom services, gross margin profile relative to mix, recurring demand from long-term accounts, and the monetization of partnerships or licensing tied to discovery programs.
2. Valuation Analysis: Public Trading Comps & Multiples for Biologic Drug Discovery Tools Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Biologic Drug Discovery Tools Companies sector
Comparable group 1: Biologic Drug Discovery Tools Companies
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
Sino Biological
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biological research reagents focusing on cytokines, small molecules, and antibodies used in tumor organoid research with applications in various signal pathways and cellular models.
- Key Products:
- Cytokines: Biochemicals that mediate and regulate immunity, inflammation, and hematopoiesis
- Small Molecules: Compounds with pharmacological activity impacting cellular pathways
- Antibodies: Proteins used for detecting and purifying biological molecules
- Protein Production: Custom production services in different expression systems
- Gene Synthesis: Custom gene synthesis and cloning services.